Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis. The emergence of HER2 targeted drugs has greatly improved the prognosis and survival of such patients. At present, for HER2 positive breast cancer patients with negative lymph nodes, chemotherapy drugs combined with trastuzumab is the current standard treatment scheme, and in most cases, chemotherapy uses a combination of two drugs, while the main beneficiaries of the target treatment of trastuzumab and pertuzumab are concentrated in the group of patients with positive lymph nodes. Can the use of target therapy to de-escalation chemotherapy and further achieve a strategy of high efficacy and low toxicity. It is planned to explore the efficacy and safety of T1-T2, HER2 positive early breast cancer patients with negative lymph nodes to achieve chemotherapy reduction based on risk stratification.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Leczenie w Szpitalu Uniwersyteckim w Pekinie z przeprowadzoną operacją usunięcia nowotworu i dokumentacją hospitalizacji
- •Potwierdzony po operacji rak piersi z inwazją, stadium T2, N0, HER2 dodatni, wraz z co najmniej jednym czynnikiem wysokiego ryzyka (G3 lub brak receptorów hormonalnych)
- •Podpisana zgoda na udział w badaniu kohortowym chorób piersi PKUPH
✗ Disqualifies
- •Brak pełnych danych klinicznych i badań pooperacyjnych (obrazy, wyniki badań)
- •Chemioterapia lub inne leczenie przed operacją
- •Rak piersi z przerzutami lub rak obu piersi
- •Niekompletna operacja usunięcia nowotworu
Simplified criteria — AI translation
Trial details
- Last updated (source)
- December 9, 2024
- Sex
- No restrictions
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
yuan peng, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.